KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...

Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...

The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...